Home About Sudair Company Overview

Company Overview

Welcome to Sudair Pharma

Welcome to Sudair Pharma

Sudair Pharma is a Saudi pharmaceutical manufacturer committed to improving lives through high-quality medicines, advanced manufacturing, and continuous innovation, while supporting the localisation of pharmaceutical production across the Kingdom and the region.

Patients served
0 M+
Registered products
0 +
Therapeutic areas
0 +
International markets
0 +

The Story of Sudair Pharma

Our Story

Driven by a vision to strengthen pharmaceutical manufacturing in Saudi Arabia, Sudair Pharma is dedicated to localising the production of advanced medicines while supporting regional healthcare needs through innovation, scientific excellence, and world-class manufacturing.

Through strategic international partnerships and continuous investment in advanced technologies, the company has expanded its manufacturing capabilities across a broad range of therapeutic areas, delivering high-quality pharmaceutical products that support healthcare systems across Saudi Arabia and international markets.

Our Journey

A timeline of milestones that reflect our growth, innovation, and commitment to better health.
  1. 2013

    The Beginning of a Vision

    • Sudair Pharma was established in February 2013, with a mission to strengthen local pharmaceutical manufacturing and improve patient access to essential therapies.
  2. Building the Foundation

    2016

    Building the Foundation

    • The foundation stone was laid, and construction began on the first specialized anti-neoplastic and high-potency manufacturing facility.
  3. 2017

    Technology Transfer Begins

    • Secured our first technology and knowledge transfer partnership for anti-neoplastic medicines.
    • Completed construction of our first dedicated anti-neoplastic manufacturing facility.
  4. 2018

    From Vision to Market

    • Registered our first portfolio of 11 products with the Saudi Food and Drug Authority (SFDA).
    • Successfully launched our first anti-neoplastic treatment.
  5. 2019

    Portfolio triples

    • Registered 3 additional products, bringing the total portfolio to 14 products.
  6. 2020

    Expanding Beyond Borders

    • Expanded our portfolio to 45 registered products, including 31 newly registered products.
    • Expanded into the Bahraini and UAE markets.
  7. 2021

    Diversification & Localisation

    • Registered 16 additional products, reaching 61 registered products.
    • Expanded into anticoagulants, anti-infectives, multiple sclerosis therapies, and epilepsy treatments.
    • Successfully localised our first anti-neoplastic product, Lenalidomide.
    • Awarded the Good Manufacturing Practice (GMP) Certificate by the Ministry of Health of Libya.
  8. 2022

    Broadening Therapeutic Reach

    • Implemented SAP S/4HANA, a state-of-the-art enterprise resource planning (ERP) system, across operations.
    • Began construction of the General Formulation Site.
    • Expanded our portfolio to 67 products across anti-neoplastic, respiratory, neurology, and anti-infective therapeutic areas.
  9. 2023

    Localisation at Scale

    • Introduced the first and only sterile high-potent manufacturing line in the Kingdom, strengthening our ability to manufacture complex injectables locally.
    • Localised the manufacturing of more than 10 pharmaceutical products, strengthening technology transfer and supply chain resilience.
  10. 2024

    A Landmark Year of Impact

    • Signed our first pharmaceutical off-take agreement.
    • Registered 20 additional products, increasing our portfolio to 95 products.
    • Successfully localised the first generic medicine for the prevention and treatment of blood clots.
    • Contributed to the treatment of more than 750,000 patients through our medicines.
    • Launched the major expansion project of the Sudair Manufacturing Complex.
    • Launched the Ghrs Program.
    • Introduced new products across anti-neoplastic, diabetes, and respiratory therapeutic areas.
  11. 2025

    Shaping the Future of Biopharma

    • Initiated construction of our dedicated insulin manufacturing facility for formulation, fill, and finish.
    • Localised 13 additional pharmaceutical products, bringing the total number of locally manufactured products to 35.
  12. 2026

    Transforming Lives

    • Entered the biosimilars market with our first registered portfolio.
    • Reached 39 fully manufactured products at Sudair Pharma facilities.
    • Registered 16 new products, increasing our total registered portfolio to 128 products.

Environmental, Health, & Safety

Sudair Pharma integrates environmental stewardship, workplace safety, and continuous improvement into every aspect of its operations through its Quality, Health, Safety & Environmental Management System (QHSE), ensuring responsible manufacturing and a safe working environment.

 

Our People الموظفون

Our People

We prioritize the health, safety, and well-being of our employees, contractors, and visitors by fostering a safe, inclusive, and supportive workplace culture.

Environment

Our Environment

We are committed to protecting the environment through responsible resource management, energy efficiency, pollution prevention, and reducing our environmental footprint.

Our Responsibility مسؤليتنا

Our Responsibility

We continuously enhance our QHSE performance through robust systems, training, innovation, and compliance with international standards to create long-term value for society.

Built in Sudair, Supplying The World

A decade of investment in local pharmaceutical manufacturing capability.